Polycyclo Ring System Having The Hetero Ring As One Of The Cyclos Patents (Class 514/100)
  • Patent number: 10329267
    Abstract: The invention addresses the problem of providing a method for producing 2-acetyl-4H,9H-naphtho[2,3-b]furan-4,9-dione that is suited to industrial production. The invention provides a method for producing 2-acetyl-4H,9H-naphtho[2,3-b]furan-4,9-dione by reacting 3-bromo-3-buten-2-one and 2-hydroxy-1,4-naphthoquinone in the presence of a solvent, then obtaining crystals of 2-acetyl-4H,9H-naphtho[2,3-b]furan-4,9-dione by adding an alcohol-based solvent and/or water to the reaction system, and treating the crystals by using a specific adsorbent in the presence of a solvent.
    Type: Grant
    Filed: July 15, 2016
    Date of Patent: June 25, 2019
    Assignee: SUMITOMO DAINIPPON PHARMA CO., LTD.
    Inventors: Toshikazu Yagi, Satoshi Suzuki, Hiroto Tatamidani, Kazuki Hashimoto
  • Patent number: 10188669
    Abstract: A method for providing to a mammal a neuroprotective effect against a brain pathology that is associated with reactive oxygen species originating from mitochondria (mROS). The method includes the step of administering to the mammal an SkQ mitochondria-targeted antioxidant in an amount effective to provide said neuroprotective effect. The SkQ mitochondria-targeted antioxidant may be administered either prophylactically or for treatment with respect to brain pathologies other than brain trauma or stroke, and may be administered for treatment of brain trauma or stroke.
    Type: Grant
    Filed: March 2, 2016
    Date of Patent: January 29, 2019
    Assignee: MITOTECH S.A.
    Inventors: Maxim Vladimirovich Skulachev, Vladimir Petrovich Skulachev, Maxim Viktorovich Egorov, Nikolai Konstantinovich Isaev, Nadezhda Anatolievna Kapay, Dmitry Borisovich Zorov, Elena Viktorovna Stelmashuk, Fedor Fedorovich Severin
  • Patent number: 10137105
    Abstract: The present disclosure provides a combination and a method for treating chronic lymphocytic leukemia (CLL).
    Type: Grant
    Filed: March 2, 2016
    Date of Patent: November 27, 2018
    Assignee: Bionomics Limited
    Inventors: Alan R. Eastman, Darcy Bates, Gabriel Kremmidiotis
  • Patent number: 10031138
    Abstract: Hierarchical films with structurally regulated functionalities through the integration of two-dimensional and three-dimensional structures to achieve ultra low nonspecific binding and high loading of molecular recognition elements, and methods for making and using the films.
    Type: Grant
    Filed: January 22, 2013
    Date of Patent: July 24, 2018
    Assignee: University of Washington through its Center for Commercialization
    Inventors: Shaoyi Jiang, Norman David Brault, Jr., Harihara S. Sundaram, Chun-Jen Huang, Qiuming Yu, Yuting Li
  • Patent number: 9919060
    Abstract: The invention relates to novel compounds for use in the treatment or prophylaxis of cancers and other proliferative conditions that are for example characterized by cells that express cytochrome P450 1B1 (CYP1B1) and allelic variants thereof. The invention also provides pharmaceutical compositions comprising one or more such compounds for use in medical therapy, for example in the treatment of prophylaxis of cancers or other proliferative conditions, as well as methods for treating cancers or other conditions in human or non-human animal patients. The invention also provides methods for identifying novel compounds for use in the treatment of prophylaxis of cancers and other proliferative conditions that are for example characterized by cells that express CYP1 B1 and allelic variants thereof. The invention also provides a method for determining the efficacy of a compound of the invention in treating cancer.
    Type: Grant
    Filed: February 6, 2017
    Date of Patent: March 20, 2018
    Assignee: University Court of the University of Dundee
    Inventors: Steven Albert Everett, Saraj Ulhaq
  • Patent number: 9695143
    Abstract: Described herein are ?9-THC prodrugs, methods of making ?9-THC prodrugs, formulations comprising ?9-THC prodrugs and methods of using ?9-THC. One embodiment described herein relates to the transdermal administration of a ?9-THC prodrug for treating and preventing diseases and/or disorders.
    Type: Grant
    Filed: February 11, 2015
    Date of Patent: July 4, 2017
    Assignee: Zynerba Pharmaceuticals, Inc.
    Inventors: Audra Lynn Stinchcomb, Miroslaw Jerzy Golinski, Dana Carmel Hammell, Jeffrey Lynn Howard
  • Patent number: 9623440
    Abstract: A method for at least partially applying a hydrophilic polymer to a measurement channel of a sensor cartridge is provided, which sensor cartridge can be replaceably inserted in an analyzer. The measurement channel comprises at least one sensor element. The method comprises inserting the sensor cartridge into the analyzer, introducing an aqueous solution containing chitosan or a chitosan derivative into the measurement channel of the sensor cartridge, and following a residence time replacing the aqueous chitosan solution with a gaseous or liquid medium, wherein residues of the chitosan or chitosan derivatives remain on the inside surface of the measurement channel and hydrophilize the surface.
    Type: Grant
    Filed: January 23, 2013
    Date of Patent: April 18, 2017
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Wolfgang Hofmann, Taghi Noormofidi, Doris Zahrl
  • Patent number: 9549922
    Abstract: The invention provides methods and compositions for use in treating diseases associated with excessive cellular proliferation, such as cancer.
    Type: Grant
    Filed: June 26, 2014
    Date of Patent: January 24, 2017
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Kenichi Nomoto, Jiayi Wu
  • Patent number: 9482664
    Abstract: Disclosed are devices and methods for detecting analytes from a sample.
    Type: Grant
    Filed: May 17, 2011
    Date of Patent: November 1, 2016
    Assignee: Sentilus Holdco LLC
    Inventors: Ashutosh Chilkoti, Angus Hucknall
  • Patent number: 9463171
    Abstract: Therapeutic ureido-sulfonamide compositions having compounds with the formula R-Q-Ar—SO2NH2 are disclosed, which compounds selectively inhibit CAIX and CAXII, and which are effective to inhibit hypoxic tumor growth, suppress metastases, and impair and deplete cancer stem cells in mammals.
    Type: Grant
    Filed: January 9, 2013
    Date of Patent: October 11, 2016
    Assignee: Welichem Biotech Inc.
    Inventors: Claudiu Supuran, Shoukat Dedhar, Paul C. McDonald, Fabrizio Carta
  • Patent number: 9328130
    Abstract: This invention relates to biology and medicine and, in particular, can be used in medicine to make a pharmaceutical composition for targeted delivery of biologically active substances into mitochondria, driven by proton electro-chemical potential in the mitochondria. This invention also relates to the method to affect an organism by the targeted delivery of biologically active compounds to mitochondria. The invention can be useful in treatment of diseases or disorders associated with not normal functioning of mitochondria, in particular diseases associated with increased production of free radicals and reactive oxygen species.
    Type: Grant
    Filed: January 10, 2008
    Date of Patent: May 3, 2016
    Assignee: MITOTECH S.A.
    Inventor: Vladimir Petrovich Skulachev
  • Patent number: 9309212
    Abstract: The present invention embraces compounds that modulate the activity of Epstein-Barr Nuclear Antigen 1 (BBNA1) protein and use thereof in methods for treating latent Epstein-Barr virus infection. R7 is a substituted or unsubstituted phenyl, pyridyl, or pyrimidinyl group. A pharmaceutical composition comprising a compound of the invention in admixture with a pharmaceutically acceptable carrier is also provide as are methods for modulating the activity of Epstein-Barr Nuclear Antigen 1 (EBNA1) protein and treating a latent EpsteinBarr virus infection with a composition of the present invention.
    Type: Grant
    Filed: May 22, 2012
    Date of Patent: April 12, 2016
    Assignee: The Wistar Institute
    Inventors: Paul M. Lieberman, Troy Messick
  • Patent number: 9274130
    Abstract: Methods for preventing or treating pain are provided. Such methods comprise administering to a subject (e.g., a human subject) an antibody or antibody fragment that binds LPA. The antibody may be a humanized monoclonal antibody.
    Type: Grant
    Filed: July 14, 2011
    Date of Patent: March 1, 2016
    Assignee: Lpath, Inc.
    Inventors: Roger A. Sabbadini, Rosalia Matteo
  • Patent number: 9241911
    Abstract: A multi-compartment capsule, comprising, a first receiving chamber comprising at least one ingredient having a first physical state, wherein said ingredient is selected from the group consisting of a nutraceutical, a vitamin, a dietary supplement and a mineral; and a second receiving chamber comprising at least one ingredient having a second physical state, wherein said ingredient is selected from the group consisting of a nutraceutical, a vitamin, a dietary supplement and a mineral; wherein said first physical state of said ingredient of said first receiving chamber being different from said second physical state of said ingredient of said second receiving chamber; and said ingredient of said first receiving chamber being different from said ingredient of said second receiving chamber.
    Type: Grant
    Filed: September 25, 2013
    Date of Patent: January 26, 2016
    Inventor: Fred H. Miller
  • Patent number: 9180079
    Abstract: A skin external preparation containing an ascorbic acid-2-phosphate derivative is characterized in that only a sodium ascorbic acid-2-phosphate-6-palmitate is formulated as the ascorbic acid-2-phosphate derivative, and the skin preparation further includes at least one betaine-type amphoteric surfactant selected from the group consisting of compounds represented by the following general formula (1) or (2) (wherein R1 represents a linear or branched alkyl group of 6 to 30 carbon atoms, and R2 represents a linear or branched alkyl group of 8 to 30 carbon atoms).
    Type: Grant
    Filed: May 2, 2012
    Date of Patent: November 10, 2015
    Assignee: SHOWA DENKO K.K.
    Inventor: Naoko Ito
  • Patent number: 9168216
    Abstract: The invention relates to a carrier for administering biologically active compounds comprising one or more C1-C4 alcohols, polyols and polymers thereof, water and one or more di and/or mono-(electron transfer agent) phosphate derivatives or complexes thereof. The carrier may be used in administering biologically active compounds, in particular pharmaceuticals including cosmetic agents.
    Type: Grant
    Filed: June 16, 2006
    Date of Patent: October 27, 2015
    Assignee: Vital Health Sciences Pty. Ltd.
    Inventors: Paul Gavin, Robert Gianello, Esra Ogru
  • Publication number: 20150140088
    Abstract: The present invention relates to the fields of chemistry and pharmacy and, in particular, to the production of novel molecular entities: esterane derivatives fused with spirostanes rings, acting upon the Central Nervous Systems (CNS). From diosgenin, a naturally occurring sapogenin, with some subsequent transformations thereof, spirosteroid derivatives of the I-IV general formula can be obtained, with a cyclopentaneperhydrophenantrene nucleus fused to a 25R-spirostanes nucleus. Such molecular entities have an anti-inflammatory and anti-glutamatergic actions that can be used to treat inflammatory, cerebrovascular, neurodegenerative, neuropsychiatric, and neurologic diseases.
    Type: Application
    Filed: December 27, 2012
    Publication date: May 21, 2015
    Inventors: Laura Garcia Pupo, Yanier Nuñez Figueredo, Juan Enrique Tacoronte Morales, Yamila Verdecia Reyes, Estael Ochoa Rodriguez, Zaldo Castro Armando
  • Publication number: 20150133401
    Abstract: The present invention provides a method for treating a proliferative disease in a patient. The method comprises administering to a patient in need thereof: a) a vascular disrupting agent and (b) at least one hypoxia targeting agent. Preferred combinations are BNC105 and Pazopanib and BNC 105 and Bortezomib.
    Type: Application
    Filed: June 3, 2013
    Publication date: May 14, 2015
    Inventors: Daniel J. Inglis, Tina C. Lavranos, Gabriel Kremmidiotis
  • Publication number: 20150087620
    Abstract: The present invention provides a compound represented by the following formula (I): wherein each symbol is as described in the DESCRIPTION, which has a superior peripheral blood lymphocyte decreasing action, and is useful for the treatment or prophylaxis of autoimmune diseases; prophylaxis or suppression of resistance or acute rejection or chronic rejection of transplantation of organ or tissue; treatment or prophylaxis of graft-versus-host (GvH) disease due to bone marrow transplantation; or treatment or prophylaxis of allergic diseases.
    Type: Application
    Filed: April 23, 2013
    Publication date: March 26, 2015
    Applicant: MITSUBISHI TANABE PHARMA CORPORATION
    Inventors: Maiko Hamada, Kaoru Tashiro, Hiroshi Sakashita, Masatoshi Kiuchi, Shuzo Takeda, Kunitomo Adachi
  • Patent number: 8937056
    Abstract: The present invention provides compounds, pharmaceutical compositions and methods for the treatment of specific cancers. Such compositions may generally comprise a compound of formula (I): wherein R1-R3 are as defined herein, or pharmaceutically acceptable salts or esters thereof; and a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: March 11, 2013
    Date of Patent: January 20, 2015
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Sergei Agoulnik, Bruce Decosta, Hong Du, Yimin Jiang, Xiang-Yi Li, Kenichi Nomoto, John (Yuan) Wang, Huiming Zhang
  • Publication number: 20150011512
    Abstract: The invention relates to novel compounds for use in the treatment or prophylaxis of cancers and other proliferative conditions that are for example characterized by cells that express cytochrome P450 1B1 (CYP1B1) and allelic variants thereof. The invention also provides pharmaceutical compositions comprising one or more such compounds for use in medical therapy, for example in the treatment of prophylaxis of cancers or other proliferative conditions, as well as methods for treating cancers or other conditions in human or non-human animal patients. The invention also provides methods for identifying novel compounds for use in the treatment of prophylaxis of cancers and other proliferative conditions that are for example characterized by cells that express CYP1 B1 and allelic variants thereof. The invention also provides a method for determining the efficacy of a compound of the invention in treating cancer.
    Type: Application
    Filed: September 12, 2014
    Publication date: January 8, 2015
    Inventors: Steven Albert Everett, Saraj Ulhaq
  • Patent number: 8901107
    Abstract: A composition which includes a salt of metformin and the use of the composition for treatment of or use in prediabetes, diabetes, lowering triglycerides and/or other conditions in mammals.
    Type: Grant
    Filed: June 21, 2013
    Date of Patent: December 2, 2014
    Assignee: Thetis Pharmaceuticals LLC
    Inventors: Banavara L. Mylari, Frank C. Sciavolino
  • Patent number: 8883765
    Abstract: Artemisinin-derived monomers and artemisinin dimers are shown to exhibit in-vitro anti-cytomegalovirus (CMV) activity. Artemisinin dimers effectively inhibited CMV replication in human foreskin fibroblasts and human embryonic lung fibroblasts with no cytotoxicity at concentrations required for complete CMV inhibition. Artemisinin dimers were found to be potent and non-cytotoxic inhibitors of CMV replication, which indicates their use as therapeutic agents for the treatment of CMV infection in humans.
    Type: Grant
    Filed: December 8, 2010
    Date of Patent: November 11, 2014
    Assignee: The John Hopkins University
    Inventors: Ravit Arav-Boger, Gary Posner
  • Patent number: 8871748
    Abstract: The present invention discloses certain polyene cyclodextrin acetals and hemiacetals that are effective in providing skin clarification, which is useful for the treatment of acne, and skin disfigurements and skin darkening resulting from acne; skin darkening from cancer, diabetes, radiation treatments, chemotherapy, and sun-burn; mitochondrial and DNA dysfunction; age spots; loss of cellular antioxidants; skin changes associated with aging including collagen loss, loss of skin pliability, loss of skin suppleness, skin wrinkles and fine lines, oxidation, damage from radiation, damage from free radicals, and damage from UV; dry skin; xerosis; ichthyosis; dandruff; brownish spots; keratoses; melasma; lentigines; liver spots; skin pigmentation including pigmented spots, dark circles under the eyes, darkened skin, and blemishes; oily skin; warts; eczema; pruritic skin; psoriasis; inflammatory dermatoses; topical inflammation; disturbed keratinization; scalp dryness, and combinations thereof.
    Type: Grant
    Filed: February 14, 2013
    Date of Patent: October 28, 2014
    Assignee: Island Kinetics Inc.
    Inventors: David Wayne Peter, John Dillon Stanek, Cheria L Orozco, Shyam K Gupta
  • Patent number: 8871276
    Abstract: The present invention discloses a dried composition comprising ?-casein micelles, assemblies and complexes thereof. The dried composition is stable in the dried state as well as upon re-suspension The dried composition retains the biological activity, drug load capacity, particle size and particle size distribution of the ?-casein micelles, assemblies and complexes comprising the active pharmaceutical ingredient, within the dried state and upon resuspension in a buffer or an aqueous pharmaceutical carrier.
    Type: Grant
    Filed: August 18, 2011
    Date of Patent: October 28, 2014
    Assignee: Technion Research and Development Foundation Ltd.
    Inventors: Yechezkel Barenholz, Dganit Danino
  • Patent number: 8865223
    Abstract: Nanoparticulate assemblies of isolated beta-casein, are useful for encapsulation of bioactive therapeutic substances, particularly therapeutic agents with poor bioavailability. These nano-sized beta-casein assemblies are preferably formed at pH values which are at least one or more pH units below or above the pI of the protein. Pharmaceutical compositions comprising the beta-casein micelles may be used to administer the agents to the GI tract for treatment of local or systemic conditions. These carriers are stable over a wide temperature range (optionally at least from about 1° C. to at least about 45° C.).
    Type: Grant
    Filed: February 11, 2009
    Date of Patent: October 21, 2014
    Assignee: Technion Research and Development Foundation Ltd.
    Inventors: Yechezkel Barenholz, Dganit Danino
  • Patent number: 8865222
    Abstract: The invention relates to a composition for the enrichment of food and/or beverage and to a method of preparing such composition. The composition comprises additive loaded beta-casein micelles which are of a diameter of about 100 nm or less. These nano-sized beta-casein assemblies are formed at pH values which are preferably one or more pH units above or below the pI of the protein (pI=5.3). More preferably the beta-casein nano-assemblies are formed at a pH range between about 6.0 and about 8, or between about 2.0 and about 4.2. The invention provides vehicles for delivery of additives via transparent beverages and other foods and drinks and/or acidic foods and drinks and/or non fat foods and drinks.
    Type: Grant
    Filed: February 11, 2009
    Date of Patent: October 21, 2014
    Assignee: Technion Research and Development Foundation Ltd.
    Inventors: Dganit Danino, Yoav D. Livney, Ory Ramon, Irina Portnoy, Uri Cogan
  • Patent number: 8846644
    Abstract: A phosphate-containing nanoparticle delivery vehicle includes nanoparticle, an active ingredient, and a phosphodiester moiety connecting the nanoparticle and the active ingredient and forms a prodrug. The nanoparticle delivery vehicle achieves the function of increasing hydrophilicity of the active ingredient and specificity against tumor cells. Advantages of the nanoparticle material include biocompatibility, magnetism and/or controllable drug release.
    Type: Grant
    Filed: July 13, 2012
    Date of Patent: September 30, 2014
    Assignee: National Cheng-Kung University
    Inventors: Jih Ru Hwu, Yu-Sern Lin, Chen-Sheng Yeh, Dar-Bin Shieh, Wu-Chou Su
  • Publication number: 20140288027
    Abstract: (?)-(S)-3-(3?-hydroxy)-butylphthalide (a compound shown by Formula I) and an ester formed of the same and an acid are proved by experiments to be applicable to treatment and prevention of cerebral ischemic diseases and have a sleep-improving function. The acid refers to a pharmaceutically acceptable inorganic or organic acid. The inorganic acid refers to nitric acid, sulfuric acid, or phosphoric acid. In addition to an acid radical, the organic acid at least comprises at least one of an amino group, a hydroxyl group, and a carboxyl group. None of the compound shown by Formula I and the ester thereof is water-soluble. An ester generated from the compound and the acid further react with an acid or a base to generate a salt which is water-soluble and is used to prepare injection preparation. The experiment proves that the salt does not stimulate vessels.
    Type: Application
    Filed: September 26, 2012
    Publication date: September 25, 2014
    Inventors: Wei Wang, Yayao Zhou, Ya'nan Liu
  • Publication number: 20140255509
    Abstract: Compositions and formulations comprising a non-neutralised tocol phosphate and a vitamin A compound, which are suitable for the treatment of inflammation and/or infection in breast or udder tissue, more particularly in a mammary gland, reducing the somatic cell count in a lactating subject and supplementing vitamin E levels in a subject.
    Type: Application
    Filed: March 2, 2012
    Publication date: September 11, 2014
    Applicant: PHOSPHAGENICS LIMITED
    Inventors: Roksan Libinaki, Robert Lee Neely
  • Patent number: 8828975
    Abstract: A phosphate-containing nanoparticle delivery vehicle includes a nanoparticle, an active ingredient, and a phosphodiester moiety connecting the nanoparticle and the active ingredient and forms a prodrug. The nanoparticle delivery vehicle achieves the function of increasing hydrophilicity of the active ingredient and specificity against tumor cells. Advantages of the nanoparticle material include biocompatibility, magnetism and/or controllable drug release.
    Type: Grant
    Filed: July 13, 2012
    Date of Patent: September 9, 2014
    Assignee: National Cheng-Kung University
    Inventors: Jih Ru Hwu, Yu-Sern Lin, Chen-Sheng Yeh, Dar-Bin Shieh, Wu-Chou Su
  • Publication number: 20140248375
    Abstract: The present invention relates generally to new chemical combinations and methods for their use in the treatment of proliferative diseases and in particular cancer.
    Type: Application
    Filed: May 16, 2014
    Publication date: September 4, 2014
    Applicant: BIONOMICS LIMITED
    Inventors: Gabriel Kremmidiotis, Annabell Leske, Tina Lavranos
  • Publication number: 20140135281
    Abstract: The present invention relates to methods and compositions comprising cyromazine for the control of bee mites and for the reduction of bee mite infestations, such as the control and reduction of infestations of parasitic bee mites, such as Varroa destructor in bee, preferably honey bee, colonies, and to the treatment of varroatosis in bees.
    Type: Application
    Filed: May 14, 2012
    Publication date: May 15, 2014
    Applicant: SYNGENTA PARTICIPATIONS AG
    Inventor: Andre Fougeroux
  • Patent number: 8716267
    Abstract: The present invention relates to novel bicyclic methyl amine derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.
    Type: Grant
    Filed: April 13, 2012
    Date of Patent: May 6, 2014
    Assignee: Allergan, Inc.
    Inventors: Janet A. Takeuchi, Ling Li, Wha Bin Im
  • Publication number: 20140107077
    Abstract: The invention provides compounds of formula I: or a salt thereof. The invention also provides pharmaceutical compositions comprising a compound of formula I, processes for preparing compounds of formula I, intermediates useful for preparing compounds of formula I and therapeutic methods using the compounds of formula I.
    Type: Application
    Filed: July 10, 2013
    Publication date: April 17, 2014
    Inventors: Ingrid Gunda Georg, Satish Prakash Patil, Ashok K. Saluja, Rohit Chugh, Selwyn M. Vickers
  • Publication number: 20140100194
    Abstract: The invention is directed to TRPM8 antagonists of Formula (I). More specifically, the present invention relates to certain novel compounds, methods for preparing compounds, compositions, intermediates and derivatives thereof and methods for treating TRPM8-mediated disorders. Pharmaceutical and veterinary compositions and methods of treating pain and various other disease states or conditions using compounds of the invention are also described.
    Type: Application
    Filed: December 5, 2013
    Publication date: April 10, 2014
    Applicant: Janssen Pharmaceutica, NV
    Inventors: Raymond W Colburn, Scott L. Dax, Christopher M. Flores, Jay M. Matthews
  • Publication number: 20140086843
    Abstract: The present invention relates to a bifunctional hydroxy-bisphosphonic acid derivative of formula (I) below: or a pharmaceutically-acceptable salt thereof, a method for producing the same, pharmaceutical compositions containing the same, and the use thereof as a medicament, as well as a compound of formula (II) below: or a pharmaceutically-acceptable salt thereof, and the use thereof for producing a vectorized molecule of therapeutic or diagnostic purpose.
    Type: Application
    Filed: March 28, 2012
    Publication date: March 27, 2014
    Applicant: ATLANTHERA
    Inventors: Maxim Egorov, Jean-Yves Goujon, Ronan Le Bot
  • Publication number: 20140072617
    Abstract: The invention relates to a method for preventing or slowing down the appearance of the effects of skin ageing, in particular for slowing down the formation of wrinkles on the face, and reducing or smoothing out the wrinkles already formed, using a tocopheryl phosphate in liposomes.
    Type: Application
    Filed: October 4, 2013
    Publication date: March 13, 2014
    Applicant: LVMH RECHERCHE
    Inventors: Marc DUMAS, Emmanuelle NOBLESSE, Valérie ALARD, Dominique QUILES, Eric PERRIER
  • Publication number: 20140017194
    Abstract: Methods and compositions containing a phorbol ester or a derivative of a phorbol ester are provided for the treatment of cytopathic diseases. Cytopathic diseases may be caused by a variety means such as viral infections like HIV and AIDS, or the development of neoplasms in a mammalian subject. The methods and compositions of the invention are effective for inhibiting de novo HIV infection, upregulating viral expression from latent provirus, inhibiting HIV-induced cytopathic effects, down regulating the HIV receptor, increasing Th1 cytokine expression, decreasing Th2 cytokine expression, increasing ERK phosphorylation, inducing apoptosis in malignant cells, inducing remission, maintaining remission, as chemotherapeutic agents, as well as for decreasing symptoms of cytopathic diseases and opportunistic infections that may accompany such diseases.
    Type: Application
    Filed: March 11, 2013
    Publication date: January 16, 2014
    Applicant: Biosuccess Biotech Co. Ltd.
    Inventors: Zheng Tao Han, Richard L. Chang
  • Publication number: 20140011773
    Abstract: A compound of formula (I), or a pharmaceutically acceptable salt thereof: The compound is used in pharmaceutical compositions and in a method of treatment of a disease or medical condition which benefits from inhibition of gap junction activity by administering to a subject suffering from such disease or condition.
    Type: Application
    Filed: July 3, 2013
    Publication date: January 9, 2014
    Inventors: Edward Savory, Martyn Pritchard, Mike Ashwood
  • Publication number: 20130345176
    Abstract: The present invention discloses esters of 4,9-dihydroxy-naphtho[2,3-b]furans and methods of making and using the same. The present invention also discloses conversion of the esters into therapeutically active 4,9-dihydroxy-naphtho[2,3-b]furans in vivo. The present invention furthermore discloses pharmaceutical compositions comprising the esters of 4,9-dihydroxy-naphtho[2,3-b]furans for the treatment of various indications including proliferative diseases.
    Type: Application
    Filed: March 4, 2011
    Publication date: December 26, 2013
    Applicant: Zhoushan Haizhongzhou Xinsheng Pharmaceuticals Co., Ltd.
    Inventors: Zhiwei Jiang, Aijin Wang, Hongwei Hu, Jiali Xu, Yuesong Hu, Xian Li, Yan Ye, Jie Wang, Qinglong Li
  • Patent number: 8609640
    Abstract: The present invention provides compounds, pharmaceutical compositions and methods for the treatment of specific cancers. Such compositions may generally comprise a compound of formula (I): wherein R1-R3 are as defined herein, or pharmaceutically acceptable salts or esters thereof; and a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: July 25, 2008
    Date of Patent: December 17, 2013
    Assignee: Eisai, Inc.
    Inventors: Sergei Agoulnik, Bruce Decosta, Hong Du, Yimin Jiang, Xiang-Yi Li, Kenichi Nomoto, John (Yuan) Wang, Huiming Zhang, Jiayi Wu
  • Patent number: 8598145
    Abstract: This invention relates to anti-cancer compounds and to methods for treating or preventing cancer. In one aspect the invention concerns mitochondrially delivered pro-oxidant anti-cancer compounds that generate reactive oxygen species and induce apoptosis of cancerous cells. The delivery moiety can be a lipophilic cation and the pro-oxidant vitamin E analogue, such as ?-tocopheryl succinate, ?-tocopheryl maleate, ?-tocopheryl maleyl amide, or 2,5,7,8-tetramethyl-2R-(4R,8R,12-trimethyltridecyl)-chroman-6-yloxyacetic acid (?-tocopheryloxyacetic acid).
    Type: Grant
    Filed: March 16, 2009
    Date of Patent: December 3, 2013
    Inventors: Stephen John Ralph, Jiri Neuzil
  • Patent number: 8592611
    Abstract: The disclosure provides novel trioxane sulfur dimers having Formula I: methods for their preparation, pharmaceutical compositions containing these compounds, and methods for treating cancer, proliferative disorders, and/or malaria using these compounds and/or compositions.
    Type: Grant
    Filed: July 17, 2009
    Date of Patent: November 26, 2013
    Assignee: The Johns Hopkins University
    Inventors: Gary H. Posner, Andrew S. Rosenthal
  • Patent number: 8585972
    Abstract: One object of the present invention is to provide a biosensor and a production method therefor, by which hydrogel that enables immobilization of a physiologically active substance can be conveniently produced using safe raw materials. The present invention provides a biosensor which comprises a substrate having a metal layer on its surface, wherein a hydrophilic polymer having a reactive functional group capable of reacting with a hydroxyl group or an amino group of a physiologically active substance is bound to the metal layer directly or indirectly via an intermediate layer.
    Type: Grant
    Filed: May 12, 2010
    Date of Patent: November 19, 2013
    Assignee: FUJIFILM Corporation
    Inventors: Taisei Nishimi, Toshihide Ezoe, Toshiaki Kubo, Hidetoshi Tomita
  • Publication number: 20130303489
    Abstract: The present invention provides compounds, pharmaceutical compositions and methods for the treatment of specific cancers. Such compositions may generally comprise a compound of formula (I): wherein R1-R3 are as defined herein, or pharmaceutically acceptable salts or esters thereof; and a pharmaceutically acceptable carrier.
    Type: Application
    Filed: March 11, 2013
    Publication date: November 14, 2013
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Sergei Agoulnik, Bruce Decosta, Hong Du, Yimin Jiang, Xiang-Yi Li, Kenichi Nomoto, John (Yuan) Wang, Huiming Zhang
  • Publication number: 20130302389
    Abstract: The present invention relates to a cosmetic composition, which comprises a combination of at least two osmolytes chosen from the group comprising taurine or a derivative thereof, inositol, betaine and trehalose. This composition is intended for restoring, maintaining or reinforcing the moisturization of the skin and/or for protecting it against different types of stress and/or for preventing or retarding the appearance of the signs of aging of the skin, or for attenuating the effects thereof, or alternatively for promoting cell or tissue longevity.
    Type: Application
    Filed: July 17, 2013
    Publication date: November 14, 2013
    Inventors: Marc Dumas, Valerie Krzuch, Delphine Pelle de Queral, Catherine Heusele
  • Patent number: 8569268
    Abstract: Disclosed is an insecticidal composition comprising by weight based on the total weight of the composition: (a) from about 9 to about 91% of one or more anthranilic diamide insecticides; and (b) from about 9 to about 91% of an acrylate/methacrylate-based diblock copolymer component having a water solubility of at least about 5% by weight at 20° C., a hydrophilic-lipophilic balance value of at least about 3, and an average molecular weight ranging from about 1,500 to about 50,000 daltons; wherein the ratio of component (b) to component (a) is about 1:10 to about 10:1 by weight. Also disclosed is a geotropic propagule coated with the insecticidal composition. Further disclosed is a liquid composition comprising the insecticidal composition, and a method for protecting a geotropic propagule and plant derived therefrom from a phytophagous insect pest.
    Type: Grant
    Filed: September 16, 2011
    Date of Patent: October 29, 2013
    Assignee: E I du Pont de Nemours and Company
    Inventor: Eric P. Holowka
  • Patent number: 8569269
    Abstract: The present invention discloses a method of treating, reducing the occurrence of, or improving the symptoms associated with a skin condition by topical application of a compound of formula (I) or a salt thereof, wherein said skin condition is selected from the group consisting of melanogenesis, oxidative damage, inflammation, skin irritation from inflammation, loss of cell adhesion, loss of desquamation, extra-cellular including connective tissue matrix breakdown and skin tone loss thereof, loss of keratinization, cellular senescence, skin aging from cellular senescence, loss of skin whiteness, loss of skin barrier function, loss of skin firmness, rosacea, skin wrinkles and fine lines from cellular senescence, cellular oxidation, loss of skin collagen, topical wounds, and combinations thereof.
    Type: Grant
    Filed: June 17, 2013
    Date of Patent: October 29, 2013
    Assignee: Island Kinetics, Inc.
    Inventors: David Wayne Peter, John Dillon Stanek, Shyam K Gupta
  • Patent number: RE47300
    Abstract: This invention relates to anti-cancer compounds and to methods for treating or preventing cancer. In one aspect the invention concerns mitochondrially delivered pro-oxidant anti-cancer compounds that generate reactive oxygen species and induce apoptosis of cancerous cells. The delivery moiety can be a lipophilic cation and the pro-oxidant moiety can be a pro-oxidant vitamin E analogue, such as ?-tocopheryl succinate, ?-tocopheryl maleate, ?-tocopheryl maleyl amide, or 2,5,7,8-tetramethyl-2R-(4R,8R,12-trimethyltridecyl)-chroman-6-yloxyacetic acid (?-tocopheryloxyacetic acid).
    Type: Grant
    Filed: December 1, 2015
    Date of Patent: March 19, 2019
    Assignee: CANCURE LIMITED
    Inventors: Stephen John Ralph, Jiri Neuzil